This special series on “Systemic and Targeted Therapies for Pancreas Ductal Adenocarcinoma” is edited by Dr. Colin Weekes from Massachusetts General Hospital, Boston, Massachusetts, USA.
Review Article on Systemic and Targeted Therapies for Pancreas Ductal Adenocarcinoma
Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities
Targeting homologous recombination addicted tumors: challenges and opportunities
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
Landscape of circulating diagnostic biomarkers in pancreatic malignancies
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma
Systemic and targeted therapies for pancreatic ductal adenocarcinoma
Disclosure:
The series “Systemic and Targeted Therapies for Pancreas Ductal Adenocarcinoma” was commissioned by the editorial office, Annals of Pancreatic Cancer without any sponsorship or funding. Colin Weekes served as the unpaid Guest Editors for the series.